EUVIMEDEUVIMED entdecken
Crossref

The NGI Pre-Separator: Designed for Formulations with Large Carrier Particles

Daryl L Roberts iD, Jolyon P Mitchell

Journal of Aerosol Medicine and Pulmonary Drug Delivery · 13.11.2026

DOI: 10.1177/19412711261506512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, online erschienen am 13.11.2026. Verfasst von Daryl L Roberts und 1 weiteren Autor:innen. Beteiligte Einrichtung: Applied Particle Principles, LLC, Hamilton, Virginia, USA. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Compendial methods recommend including a pre-separator (PS) before the multi-stage impactor when testing dry powder inhalers (DPIs) for emitted aerosol aerodynamic particle size distribution (APSD). For data analysis, they are either silent or treat the PS as a “non-sizing” component. The overall message is “use the PS but ignore what it collects.” The Next Generation Impactor (NGI) PS reinforces this mindset because it was specifically designed for testing carrier-particle-based DPIs wherein any API in the PS results from a failure to detach from the large carrier particles. However, users with carrier-free DPI formulations might wonder what to do if drug is found in the PS and if it is technically justified to omit this component, thereby increasing laboratory throughput by relying on the NGI alone to provide accurate APSD metrics.

Methods

Particle capture efficiency curves for the NGI PS were constructed from the published calibration data at flow rates of 15, 30, 60, and 100 L/min. These curves and those published for NGI stages 1–7 enabled calculation of how model input aerosols disperse throughout an NGI with or without a PS. APSD metrics were subsequently estimated from these calculated API mass fractions and then compared with and without the PS.

Results

The presence of the PS yielded APSD metrics for the model aerosols that were almost indistinguishable from those obtained without the PS, accounting for the API mass recovered from the PS as if it had collected on an impactor stage.

Conclusions

The PS is necessary when and only when the formulation contains large carrier particles. Consequently, for carrier-free formulations, method validation with no PS is likely to succeed. If for any reason it is retained in the test method of a carrier-free formulation, the PS should be treated like an impactor stage for APSD data analysis purposes.

Schlagwörter

Stichwörter der Autor:innen

APSD data analysisgravitational settlinginertial impactionnext generation impactorpre-separator

Autor:innen und Institutionen

  • Applied Particle Principles, LLC, Hamilton, Virginia, USA.
  • Jolyon Mitchell Inhaler Consulting Services Inc, London, Canada.

ORCID-Profile: Daryl L Roberts

Zitieren

APA

Roberts, D. L., & Mitchell, J. P. (2026). The NGI Pre-Separator: Designed for Formulations with Large Carrier Particles. Journal of Aerosol Medicine and Pulmonary Drug Delivery. https://doi.org/10.1177/19412711261506512

Vancouver

Roberts DL, Mitchell JP. The NGI Pre-Separator: Designed for Formulations with Large Carrier Particles. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2026. doi:10.1177/19412711261506512

BibTeX
@article{Roberts2026,
  author = {Roberts, Daryl L and Mitchell, Jolyon P},
  title = {The NGI Pre-Separator: Designed for Formulations with Large Carrier Particles},
  journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
  year = {2026},
  doi = {10.1177/19412711261506512}
}
Kostenlos starten →